7results about How to "Reduce dosing frequency" patented technology

This invention discloses a nystatin microsphere with targeted enhanced antifungal function, its preparation method, and its application. The microsphere uses sodium alginate as a carrier, internally encapsulating the antifungal drug nystatin. The surface is covalently modified with the β-glucan binding domain of the Dectin-1 protein, constructing a smart drug delivery system with fungal targeting function. The microsphere preparation process is simple and reproducible, and can be scalable using an emulsion-ionic crosslinking method combined with protein coupling technology. In vitro characterization shows that the microspheres have uniform particle size and stable dispersion, and Dectin-1 modification significantly enhances their specific binding ability against Candida albicans. This targeted delivery system, while successfully preserving drug activity, significantly improves the antifungal efficiency of nystatin through Dectin-1-mediated targeting, achieving efficacy close to that of free drug, and providing a new strategy for constructing highly efficient and long-acting antifungal agents.

This invention relates to the fields of biomedicine and nanomaterials technology, and provides a bilayer core-shell nanoparticle composite thermosensitive gel for postoperative analgesia, its preparation method, and its applications. The bilayer core-shell nanoparticles comprise: a core of PLGA nanoparticles loaded with magnesium, and a shell of a lipid bilayer loaded with bupivacaine. The composite thermosensitive gel is made by uniformly dispersing the bilayer core-shell nanoparticles in a thermosensitive gel material. By constructing a structure with a lipid shell loaded with bupivacaine and a PLGA core loaded with magnesium, and combining it with a thermosensitive gel, this invention achieves rapid release of bupivacaine for acute postoperative analgesia, and sustained slow release of magnesium ions for long-term anti-inflammatory and repairing effects. This perfectly meets the temporal requirements of postoperative pain management and has broad clinical application prospects.

The invention discloses a fusion polypeptide RAT-1 and application thereof in hypertension treatment. The topological structure of the fusion polypeptide is a kidney targeting head-ACE2 functional segment-MMP responsive connexon-AT1 receptor antagonism segment, and the full-length sequence is as shown in SEQ ID No: 1. The kidney targeting head can be specifically combined with megalin receptors of renal tubular epithelial cells to realize kidney targeting delivery; the ACE2 functional segment can efficiently degrade angiotensin II; the MMP responsive connexon is specifically cut in a focus microenvironment, and an AT1 receptor antagonism segment is released; the AT1 receptor antagonist segment can block the receptor signal channel of angiotensin II. The fusion polypeptide has good plasma stability, shows a powerful and long-acting antihypertensive effect in a spontaneous hypertension rat model, is remarkable in kidney targeting, and can relieve renal fibrosis and protect podocyte functions. The fusion polypeptide disclosed by the invention realizes a synergistic effect of targeted delivery, enzymolysis catalysis, response release and receptor antagonism, and can be used for preparing hypertension treatment medicines and kidney protection medicines.

The invention relates to the technical field of medical drug preparation, in particular to a total glucosides of paeony nano preparation for treating inflammatory diseases and a preparation method of the total glucosides of paeony nano preparation. The nanogel dispersoid is formed by self-assembling molecules in a water phase through thermal induction gelatinization and a subsequent cooling process; the mass ratio of the total glucosides of paeony to the starch is (1: 10)-(1: 50); the average hydrated particle size of gel particles in the nanogel dispersion ranges from 80 nanometers to 300 nanometers, and the polydispersity index of the gel particles is smaller than 0.3. According to the total glucosides of paeony nano preparation for treating inflammatory diseases and the preparation method thereof, the process is simple, the cost is low, complicated equipment or organic solvents are not needed, the preparation is very suitable for industrial production, edible starch is taken as a carrier material, the biocompatibility is excellent, the safety is high, the enrichment of medicines at inflammatory parts can be effectively improved, the action time can be prolonged, and the application prospect is wide. Therefore, curative effect is improved, and administration frequency is reduced.

The invention discloses a preparation method of pH gradient active drug loading type maqui berry anthocyanin-curcumin compound lipidosome, belongs to the fields of biological medicines, food science and nutritional health-care products, and particularly relates to a nano drug delivery system and preparation of functional foods and dietary supplements. According to the method, the water-soluble maqui berry anthocyanin and the fat-soluble curcumin are efficiently entrapped at the same time by utilizing a unique double-layer structure of the lipidosome and through a film dispersion-hydration technology. Soybean lecithin and cholesterol are used as main membrane materials, tea polyphenol or vitamin E and other antioxidants are combined, and curcumin is induced to transmembrane-transfer from a lipid bilayer membrane to an internal water phase through precise pH gradient control and mild heating, so that the encapsulation efficiency of curcumin is remarkably improved. Then, through the steps of high-pressure microjet homogenization, low-temperature dialysis and the like, the maqui berry anthocyanin-curcumin compound liposome which is uniform in particle size, high in stability and excellent in encapsulation efficiency is prepared.

This invention relates to the field of pharmaceutical preparation technology, specifically to a sulfachlorpyridazine sodium-methotrexate suspension, its preparation method, and its application. The sulfachlorpyridazine sodium-methotrexate suspension of this invention comprises the following components per 100 ml: 20-50 g of sulfachlorpyridazine sodium, 4-10 g of methotrexate, 0.1-0.25 g of suspending agent, 0.05-0.125 g of wetting agent, 0.2-0.5 g of antioxidant, 0.1-0.25 g of disodium edetate, and purified water to a final volume of 100 ml. The suspension prepared by this invention can delay the in vivo clearance of sulfachlorpyridazine sodium, prolong the synergistic effect time, and improve its bioavailability; in the treatment of coccidiosis infection in chickens and sheep, it can significantly improve weight gain, reduce intestinal lesion values, rapidly clear oocysts, and maintain a long-lasting protective effect after drug withdrawal.

This invention discloses the application of Z944 in the preparation of drugs for treating knee osteoarthritis. Z944 can simultaneously promote the repair of knee cartilage and inhibit neuropathic pain, overcoming the shortcomings of existing KOA therapies, such as single target, limited efficacy, and inability to block the core pathological cycle of the disease. The mechanism of action of Z944 lies in its ability to simultaneously inhibit abnormal discharge of pain neurons and block the catabolism signals of chondrocytes, thereby fundamentally intervening in the vicious cycle of cartilage degeneration and pain transmission in knee osteoarthritis. Compared with existing therapies that target only a single pathological link, this invention achieves a synergistic therapeutic effect greater than the sum of its parts (1+1>2). Its efficacy stems from blocking the core mechanism of the disease, thus being more fundamental and lasting.